Literature DB >> 17916217

Psoriasis patients show signs of insulin resistance.

S Boehncke1, D Thaci, H Beschmann, R J Ludwig, H Ackermann, K Badenhoop, W-H Boehncke.   

Abstract

BACKGROUND: Recent observations suggest that psoriasis is a risk factor for the development of coronary artery calcification which in turn represents an indicator for atherosclerosis.
OBJECTIVE: To clarify a possible pathogenetic link between psoriasis and atherosclerosis, we studied the metabolic state of patients with psoriasis.
METHODS: Thirty-nine consecutive patients with moderate-to-severe plaque-type psoriasis were enrolled in the study. Detailed information was obtained on the patients' clinical picture and history of psoriasis, smoking habits and medication. The body mass index (BMI) of the patients was calculated. Laboratory investigations focused on values for inflammation, lipid profile and multiple cytokines. The intima-media thickness of the carotid artery was measured by ultrasound, and an oral glucose tolerance test was performed to calculate the homeostasis model assessment of insulin resistance (HOMA).
RESULTS: Numerous well-recognized correlations such as between BMI and HOMA (P < 0.02) as well as BMI and vessel wall thickness (P < 0.05) were successfully reproduced, thus confirming consistency of our dataset. With regard to psoriasis, we observed a significant correlation between the Psoriasis Area and Severity Index (PASI) score and insulin secretion. Moreover, the PASI score was significantly correlated with serum resistin levels--a cytokine known to be increased in insulin resistance.
CONCLUSIONS: Taken together, several measurements indicative of insulin resistance were found to be significantly correlated with the PASI score. The concept of insulin resistance as a consequence of chronic inflammation and possible pathogenetic cause for comorbidities known to be associated with psoriasis is supported by these data. Our findings validate further studies on larger cohorts as well as interventional studies.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17916217     DOI: 10.1111/j.1365-2133.2007.08190.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  41 in total

1.  Platelet-activating factor blockade inhibits the T-helper type 17 cell pathway and suppresses psoriasis-like skin disease in K5.hTGF-β1 transgenic mice.

Authors:  Tej Pratap Singh; Barbara Huettner; Harald Koefeler; Gerlinde Mayer; Isabella Bambach; Katrin Wallbrecht; Michael P Schön; Peter Wolf
Journal:  Am J Pathol       Date:  2011-02       Impact factor: 4.307

2.  Clinico-biochemical correlation between psoriasis and insulin resistance.

Authors:  Suparna Dhara; Anindya Dasgupta; Jayanta Kumar Rout; Ushasi Banerjee; Sayantan Dasgupta; Arindam Ghosh
Journal:  Indian J Clin Biochem       Date:  2014-01-23

Review 3.  [Comorbidities and psoriasis. Impact on clinical practice].

Authors:  S Gerdes; U Mrowietz
Journal:  Hautarzt       Date:  2012-03       Impact factor: 0.751

Review 4.  Unmet Needs in the Field of Psoriasis: Pathogenesis and Treatment.

Authors:  Wolf-Henning Boehncke; Nicolo Costantino Brembilla
Journal:  Clin Rev Allergy Immunol       Date:  2018-12       Impact factor: 8.667

5.  Serum Visfatin, Fetuin-A, and Pentraxin 3 Levels in Patients With Psoriasis and Their Relation to Disease Severity.

Authors:  Gökhan Okan; Adile Merve Baki; Eda Yorulmaz; Semra Doğru-Abbasoğlu; Pervin Vural
Journal:  J Clin Lab Anal       Date:  2015-04-13       Impact factor: 2.352

6.  Ultraviolet Phototherapy Management of Moderate-to-Severe Plaque Psoriasis: An Evidence-Based Analysis.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2009-11-01

Review 7.  Does treatment of psoriasis reduce the risk of cardiovascular disease?

Authors:  Sarah Churton; Liza Brown; Thuzar M Shin; Neil J Korman
Journal:  Drugs       Date:  2014-02       Impact factor: 9.546

8.  Topical corticosteroids and the risk of diabetes mellitus: a nested case-control study in the Netherlands.

Authors:  Michiel W van der Linden; Fernie J A Penning-van Beest; Tamar Nijsten; Ron M C Herings
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

Review 9.  Psoriasis and metabolic disease: epidemiology and pathophysiology.

Authors:  Rahat S Azfar; Joel M Gelfand
Journal:  Curr Opin Rheumatol       Date:  2008-07       Impact factor: 5.006

10.  Obesity in psoriasis: leptin and resistin as mediators of cutaneous inflammation.

Authors:  A Johnston; S Arnadottir; J E Gudjonsson; A Aphale; A A Sigmarsdottir; S I Gunnarsson; J T Steinsson; J T Elder; H Valdimarsson
Journal:  Br J Dermatol       Date:  2008-06-28       Impact factor: 9.302

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.